Lymphoma Clinical Trials in Chicago

Showing 521-540 of 559 trials

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

NCT00002759

Phase I trial to study the effectiveness of irinotecan plus cyclosporine and phenobarbital in treating patients who have solid tumors or lymphoma that is refractory to standard therapy. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Cyclosporine and phenobarbital may enhance the effectiveness of irinotecan.

Drug/Agent Toxicity by Tissue/OrganLymphomaNeutropenia+2 more

National Cancer Institute (NCI)3 participantsStarted Jun 1996

Chicago, Illinois, United States

COMPLETEDPhase 22.2 miles

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00006102

Phase II trial to study the effectiveness of rebeccamycin analogue in treating children who have solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Brain and Central Nervous System TumorsLymphomaNeuroblastoma+3 more

National Cancer Institute (NCI)200 participantsStarted Jul 2000

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +223 more locations

Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma

506U78 in Treating Patients With Lymphoma

Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hodgkin's Disease

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Aminocamptothecin in Treating Patients With Refractory or Recurrent Hodgkin's Disease or Non-Hodgkin's Lymphoma

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

Other Conditions in Chicago